France's Ipsen agrees to buy Clementia Pharmaceuticals in a deal worth up to $1.31 billion.
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
Predicted price would be nearly $3 billion over Spark's market cap as of Friday's close, but Roche spokesman claims report is 'market rumor.'
AbbVie to provide multi-million-dollar financing to Voyager to develop and commercialize potential Parkinson's treatment.
Bausch Health swings to a loss in the fourth quarter but issues positive revenue guidance for fiscal 2019.
One already is up nicely on its results, while the other two should issue reports of interest in the next few days.
Medtronic raises its full-year earnings forecast above analysts' estimates.
This biotechnology company got it's start California. Watch 'Behind the Label' TheStreet's new video series to learn more.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.